AU2021338706A1 - Ribitol treatment - Google Patents
Ribitol treatment Download PDFInfo
- Publication number
- AU2021338706A1 AU2021338706A1 AU2021338706A AU2021338706A AU2021338706A1 AU 2021338706 A1 AU2021338706 A1 AU 2021338706A1 AU 2021338706 A AU2021338706 A AU 2021338706A AU 2021338706 A AU2021338706 A AU 2021338706A AU 2021338706 A1 AU2021338706 A1 AU 2021338706A1
- Authority
- AU
- Australia
- Prior art keywords
- day
- ribitol
- dose
- comprises administering
- method comprises
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Molecular Biology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063076761P | 2020-09-10 | 2020-09-10 | |
| US63/076,761 | 2020-09-10 | ||
| PCT/US2021/049677 WO2022056137A1 (en) | 2020-09-10 | 2021-09-09 | Ribitol treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2021338706A1 true AU2021338706A1 (en) | 2023-05-25 |
Family
ID=80629815
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021338706A Pending AU2021338706A1 (en) | 2020-09-10 | 2021-09-09 | Ribitol treatment |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230364118A1 (https=) |
| EP (1) | EP4210708A4 (https=) |
| JP (1) | JP2023544249A (https=) |
| KR (1) | KR20230069941A (https=) |
| CN (1) | CN117355310A (https=) |
| AU (1) | AU2021338706A1 (https=) |
| CA (1) | CA3191582A1 (https=) |
| IL (1) | IL301088A (https=) |
| MX (1) | MX2023001881A (https=) |
| WO (1) | WO2022056137A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10434113B2 (en) | 2016-12-16 | 2019-10-08 | The Charlotte Mecklenburg Hospital Authority | Compositions and methods for treating muscular dystrophy and other disorders |
| AU2020283556A1 (en) | 2019-05-28 | 2022-01-06 | The Charlotte-Mecklenburg Hospital Authority D/B/A Atrium Health | Compositions and methods of making ribitol |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10245235B2 (en) * | 2016-12-16 | 2019-04-02 | The Charlotte-Mecklenburg Hospital Authority | Compositions and methods for treating muscular dystrophy and other disorders |
| US20200061092A1 (en) * | 2018-08-24 | 2020-02-27 | The Charlotte Mecklenburg Hospital Authority D/B/A Atrium Health | Methods and compositions for treating disorders associated with muscle weakness |
-
2021
- 2021-09-09 AU AU2021338706A patent/AU2021338706A1/en active Pending
- 2021-09-09 IL IL301088A patent/IL301088A/en unknown
- 2021-09-09 WO PCT/US2021/049677 patent/WO2022056137A1/en not_active Ceased
- 2021-09-09 MX MX2023001881A patent/MX2023001881A/es unknown
- 2021-09-09 CN CN202180073484.0A patent/CN117355310A/zh active Pending
- 2021-09-09 US US18/044,747 patent/US20230364118A1/en active Pending
- 2021-09-09 CA CA3191582A patent/CA3191582A1/en active Pending
- 2021-09-09 JP JP2023515723A patent/JP2023544249A/ja active Pending
- 2021-09-09 KR KR1020237010497A patent/KR20230069941A/ko active Pending
- 2021-09-09 EP EP21867600.5A patent/EP4210708A4/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3191582A1 (en) | 2022-03-17 |
| CN117355310A (zh) | 2024-01-05 |
| EP4210708A1 (en) | 2023-07-19 |
| EP4210708A4 (en) | 2024-10-23 |
| WO2022056137A1 (en) | 2022-03-17 |
| IL301088A (en) | 2023-05-01 |
| JP2023544249A (ja) | 2023-10-23 |
| MX2023001881A (es) | 2023-04-03 |
| US20230364118A1 (en) | 2023-11-16 |
| KR20230069941A (ko) | 2023-05-19 |
| WO2022056137A9 (en) | 2022-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12427161B2 (en) | Methods for treating and pharmaceutical compositions | |
| JP6612370B2 (ja) | ポンペ病の処置のための投与計画 | |
| JP2026035578A (ja) | ファブリー病の治療用投薬レジメン | |
| US20110009460A1 (en) | Compositions and methods for treating amyotrophic lateral sclerosis | |
| TW200808324A (en) | Method for shortening hospital stay in patients with congestive heart failure and acute fluid overload | |
| US20230364118A1 (en) | Ribitol treatment | |
| WO2012154779A1 (en) | Combinations of oxybutynin and salivary stimulants for the treatment of overactive bladder | |
| WO2012154892A1 (en) | Combinations of propiverine and salivary stimulants for the treatment of overactive bladder | |
| JP2014513689A (ja) | 過活動膀胱の治療のためのトロスピウムと唾液分泌刺激剤の組合せ | |
| HK40112795A (en) | Dosing regimens for the treatment of pompe disease | |
| WO2025068949A1 (en) | Emrusolmin for use in treating multiple system atrophy | |
| WO2025212841A1 (en) | Compositions and methods for treating diseases and disorders associated with muscle weakness | |
| Kassem et al. | A Review of Patisiran (ONPATTROÒ) for the Treatment of Polyneuropathy in People with Hereditary Transthyretin Amyloidosis | |
| HK40036814A (en) | Dosing regimens for the treatment of fabry disease | |
| WO2012154778A1 (en) | Combinations of imidafenacin and salivary stimulants for the treatment of overactive bladder | |
| NZ615726B2 (en) | Dosing regimens for the treatment of fabry disease |